全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

High-Performance Liquid Chromatography Determination of Meloxicam and Piroxicam with Ultraviolet Detection

DOI: 10.1155/2014/521697

Full-Text   Cite this paper   Add to My Lib

Abstract:

A simple accurate and sensitive high-performance liquid chromatographic method for the determination of meloxicam and piroxicam concentrations in small volume plasma samples has been developed. Following a liquid extraction using chloroform, samples were separated by reversed-phase high-performance liquid chromatography on an XBridge C18 column (4.6?×?250?mm) and quantified using ultraviolet detection at 360?nm. The mobile phase was a mixture of water with glacial acetic acid (pH 3.0) and acetonitrile (50?:?50), with a flow rate of 1.0?mL/min. The standard curve ranged from 5 to 10,000?ng/mL for meloxicam in bearded dragon (Pogona vitticeps) plasma and piroxicam in crane (Grus rubicunda) plasma. Intra- and interassay variability for meloxicam and piroxicam were less than 10% and the average recovery was greater than 90% for both drugs. This method was developed in bearded dragon and crane plasma and should be applicable to any species, making it useful for those investigators dealing with small sample volumes, particularly when conducting pharmacokinetics studies which require multiple sampling from the same animal. 1. Introduction Meloxicam, 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1λ6,2-benzothiazine-3-carboxamide, and piroxicam, 4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-yl-1λ6,2-benzothiazine-3-carboxamide, are nonsteroidal anti-inflammatory drugs (NSAIDs) with analgesic properties. They are generally used to treat osteoarthritis and rheumatoid arthritis; however, they can be used for other painful conditions such as injuries, cancer surgery, and dental infections. Meloxicam preferentially inhibits the cyclooxygenase-2 (COX-2) enzyme over COX-1. The ability to only inhibit the inflammatory COX proved to be revolutionary for pain management. The introduction of COX-2 preferential NSAIDs has reduced stomach and intestinal side effects. While piroxicam is used to treat painful conditions, it has recently been used in a variety of protocols to treat squamous cell carcinoma and hemangiosarcoma. Meloxicam can be metabolized to as many as four biologically inactive metabolites depending on the species; however, the 5-hydroxy methyl derivative is the most common metabolite. Piroxicam metabolism occurs via a cytochrome P450 2C isoform to multiple biologically inactive metabolites, with 5-hydroxy-prioxicam being the most common. Nonsteroidal anti-inflammatory drugs are commonly used in large and small veterinary practices for relief of pain, fever, and inflammation. Increasing public awareness of animal welfare will likely continue to make

References

[1]  A. J. Kreuder, J. F. Coetzee, L. W. Wulf et al., “Bioavailability and pharmacokinetics of oral meloxicam in llamas,” BMC Veterinary Research, vol. 8, article 85, 2012.
[2]  P. R. Malreddy, J. F. Coetzee, B. Kukanich, and R. Gehring, “Pharmacokinetics and milk secretion of gabapentin and meloxicam co-administered orally in Holstein-Friesian cows,” Journal of Veterinary Pharmacology and Therapeutics, vol. 36, no. 1, pp. 14–20, 2013.
[3]  J.-W. Bae, C.-I. Choi, C.-G. Jang, and S.-Y. Lee, “Effects of CYP2C9*1/*13 on the pharmacokinetics and pharmacodynamics of meloxicam,” British Journal of Clinical Pharmacology, vol. 71, no. 4, pp. 550–555, 2011.
[4]  H. Zhang and H.-K. Choi, “Analysis of meloxicam by high-performance liquid chromatography with cloud-point extraction,” Analytical and Bioanalytical Chemistry, vol. 392, no. 5, pp. 947–953, 2008.
[5]  J.-W. Bae, M.-J. Kim, C.-G. Jang, and S.-Y. Lee, “Determination of meloxicam in human plasma using a HPLC method with UV detection and its application to a pharmacokinetic study,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 859, no. 1, pp. 69–73, 2007.
[6]  A. Medvedovici, F. Albu, C. Georgita, C. Mircioiu, and V. David, “A non-extracting procedure for the determination of meloxicam in plasma samples by HPLC-DIODE Array Detection,” Arzneimittel-Forschung, vol. 55, no. 6, pp. 326–331, 2005.
[7]  H. Blain, C. Boileau, F. Lapicque et al., “Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use,” British Journal of Clinical Pharmacology, vol. 53, no. 3, pp. 255–265, 2002.
[8]  D. Turck, U. Busch, G. Heinzel, and H. Narjes, “Clinical pharmacokinetics of meloxicam,” Arzneimittel Forschung-Drug Research, vol. 47, no. 3, pp. 253–258, 1997.
[9]  J. Schmid, U. Busch, G. Heinzel, G. Bozler, S. Kaschke, and M. Kummer, “Pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects,” Drug Metabolism and Disposition, vol. 23, no. 11, pp. 1206–1214, 1995.
[10]  J. L. Wiesner, A. D. de Jager, F. C. W. Sutherland, et al., “Sensitive and rapid liquid chromatography-tandem mass spectrometry method for the determination of meloxicam in human plasma,” Journal of Chromatography B, vol. 785, no. 1, pp. 115–121, 2003.
[11]  P.-L. Toutain, N. Reymond, V. Laroute et al., “Pharmacokinetics of meloxicam in plasma and urine of horses,” American Journal of Veterinary Research, vol. 65, no. 11, pp. 1542–1547, 2004.
[12]  H.-K. Han and H.-K. Choi, “Improved absorption of meloxicam via salt formation with ethanolamines,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 65, no. 1, pp. 99–103, 2007.
[13]  B. Dasandi, H. Saroj, and K. M. Bhat, “LC determination and pharmacokinetics of meloxicam,” Journal of Pharmaceutical and Biomedical Analysis, vol. 28, no. 5, pp. 999–1004, 2002.
[14]  H. Modesto Rigato, G. Duarte Mendes, N. Carter do Carmo Borges, and R. A. Moreno, “Meloxicam determination in human plasma by high-performance liquid chromatography coupled with tandem mass spectrometry (LC-MS-MS) in Brazilian bioequivalence studies,” International Journal of Clinical Pharmacology and Therapeutics, vol. 44, no. 10, pp. 489–498, 2006.
[15]  W. R. G. Baeyens, G. van der Weken, E. D'haeninck, et al., “Application of an alkyl-diol silica precolumn in a column-switching system for the determination of meloxicam in plasma,” Journal of Pharmaceutical and Biomedical Analysis, vol. 32, no. 4-5, pp. 839–846, 2003.
[16]  K. Baert and P. de Backer, “Disposition of sodium salicylate, flunixin and meloxicam after intravenous administration in broiler chickens,” Journal of Veterinary Pharmacology and Therapeutics, vol. 25, no. 6, pp. 449–453, 2002.
[17]  J. A. Palma-Aguirre, M. Lopez-Gamboa, L. Cari?o, V. Burke-Fraga, and M. González-de la Parra, “Relative bioavailability of two oral formulations of piroxicam 20?mg: a single-dose, randomized-sequence, open-label, two-period crossover comparison in healthy Mexican adult volunteers,” Clinical Therapeutics, vol. 32, no. 2, pp. 357–364, 2010.
[18]  L. Edno, F. Bressolle, B. Combe, and M. Galtier, “A reproducible and rapid HPLC assay for quantitation of piroxicam in plasma,” Journal of Pharmaceutical and Biomedical Analysis, vol. 13, no. 6, pp. 785–789, 1995.
[19]  M. T. Maya, J. P. Pais, and J. Morais, “A rapid method for the determination of piroxicam in plasma by high-performance liquid chromatography,” Journal of Pharmaceutical and Biomedical Analysis, vol. 13, no. 3, pp. 319–322, 1995.

Full-Text

Contact Us

[email protected]

QQ:3279437679

WhatsApp +8615387084133